Clinical trial · Observational
Follow-up Strategy for Esophageal Cancer Patients
An Optimized Post-surgery Follow-up Strategy for Patients With Esophageal Cancer
NCT06045715CI-TRIAL-00069819unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The recurrence risk of patients with esophageal cancer was stratified by integrating different stages and pathological factors. The risk of recurrence was dynamically estimated for each group of patients, and the optimal follow-up strategy was developed based on the recurrence risk.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophagus Cancer | Esophageal Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| follow-up with different time intervals | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- follow-up
- description
- patients were follow-up with different time intervals
- interventionNames
- Other: follow-up with different time intervals
Primary outcomes (1)
- measure
- disease-free survival
- timeFrame
- 2008-2020
- description
- disease-free survival
Secondary outcomes (2)
- measure
- local relapse-free survival
- timeFrame
- 2008-2020
- measure
- distant metastasis-free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: (1) Patients aged between 18 and 80 years old; (2) Pathological diagnosis as esophageal squamous cell carcinoma or adenocarcinoma; (3) Patients underwent esophagectomy and received R0 resection. Exclusion Criteria: (1) Patients with secondary primary tumor; (2) Patients who died within 30 days after surgery or died of post-operation complications; (3) Patients missing essential clinical information, such as operation record, pathological diagnosis, and follow-up data; (4) Patients with radiologically or histologically confirmed distant metastasis; (5) Patients previously underwent endoscopic mucosal resection or definitive radiochemotherapy as initial treatment.
References
Publications (0)
Data not yet available
No reference posted for this study.